H. Ballentine Carter MDProfessor of Urology, Oncology, Johns Hopkins Medicine, Baltimore, Maryland; Director, Division of Adult Urology, Brady Urological Institute
Dr. Carter is a Professor of Urology, James Buchanan Brady Urological Institute at Johns Hopkins School of Medicine. He was born in Lake City, S.C. He graduated from Furman University in Greenville, S.C. with a B.S. in biology and received the Distinguished Alumni Award from Furman University in 2005. He earned his M.D. degree from the Medical University of S.C. in 1981 and completed his urology residency at the New York Hospital-Cornell Medical Center in 1987. In 1989 Dr. Carter completed an AUA scholarship in oncology at Johns Hopkins and joined their urology facility.
In 1998, Dr. Carter was promoted to Professor of Urology and Oncology at the Johns Hopkins School of Medicine where he is Director of Adult Urology. He specializes in the management of prostate disease with a focus on prostate cancer. Dr. Carter established an Active Surveillance program for prostate cancer at Johns Hopkins in 1995 that has become one of the largest and longest running longitudinal studies of this kind.
Dr. Carter is a Diplomate of the American Board of urology and a member of the American Urological Association, the Society of Urological Oncology, the American Society of Clinical Oncologists, and the American Association of Genitourinary Surgeons.
Recent Contributions to PracticeUpdate:
- Effect of the Recommendation Against Screening on Prostate Cancer Diagnoses
- Patients Present With More Advanced Prostate Cancer Since the USPSTF Screening Recommendations
- Multiparametric MRI and Fusion Biopsies in the Active Surveillance Setting
- Targeted Prostate Biopsy in Select Men for Active Surveillance
- Low Additional Yield Argues Against Routine Biopsy in Active Surveillance of Prostate Cancer
- Predicting Individual Risk of Over-Diagnosis in PSA-Detected Disease
- Is There a Difference Between Low-Risk and Very Low-Risk Prostate Cancer? A Conversation With Ballentine Carter
- Impact of Immediate TRUS Rebiopsy in a Patient Cohort Considering Active Surveillance for Favorable Risk Prostate Cancer